Cholesterol Variability and Mortality, MI, and Stroke Risk Cholesterol Variability and Mortality, MI, and Stroke Risk

Is high visit-to-visit variability in lipid levels an independent predictor of adverse cardiometabolic events?European Heart Journal
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Related Links:

Fight Aging! provides a weekly digest of news and commentary for thousands of subscribers interested in the latest longevity science: progress towards the medical control of aging in order to prevent age-related frailty, suffering, and disease, as well as improvements in the present understanding of what works and what doesn't work when it comes to extending healthy life. Expect to see summaries of recent advances in medical research, news from the scientific community, advocacy and fundraising initiatives to help speed work on the repair and reversal of aging, links to online resources, and much more. This content is...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Conclusions: Iron-related transporters in liver and lower/upper portions of small intestine play critical roles in NASH development. Methods: Expression of iron metabolism-related genes in liver and small intestine was analyzed in stroke-prone spontaneously hypertensive rats (SHR-SP), which develop NASH. Five-week-old SHR-SP fed ND or HFCD were examined. mRNA and protein levels of iron metabolism-related genes in liver and small intestine from 12- and 19-week-old rats were evaluated by real-time RT-PCR and immunohistochemistry or Western blot. PMID: 29899851 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
CONCLUSIONS: Elevated plasma concentrations of ceramides are independently associated with major adverse cardiovascular events in patients with and without coronary artery disease. PMID: 29903731 [PubMed - as supplied by publisher]
Source: Arteriosclerosis, Thrombosis and Vascular Biology - Category: Cardiology Authors: Tags: Arterioscler Thromb Vasc Biol Source Type: research
HIGH cholesterol can increase your chance of developing a serious health condition such as heart disease, heart attack and stroke. But how do you know if you ’re at risk? Dr Chris Steele took to This Morning to warn of particular sign to look out for involving the eyelids.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Response by Bohula et al to Letters Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". Circulation. 2018 Jun 12;137(24):2662-2663 Authors: Bohula EA, Wiviott SD, Giugliano RP, Park JG, Murphy SA, Cannon CP, Braunwald E PMID: 29891625 [PubMed - in process]
Source: Circulation - Category: Cardiology Authors: Tags: Circulation Source Type: research
Letter by Koh Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". Circulation. 2018 Jun 12;137(24):2660-2661 Authors: Koh KK PMID: 29891624 [PubMed - in process]
Source: Circulation - Category: Cardiology Authors: Tags: Circulation Source Type: research
Letter by Cordero et al Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". Circulation. 2018 Jun 12;137(24):2658-2659 Authors: Cordero A, Bertomeu-González V, Rodriguez-Mañero M PMID: 29891623 [PubMed - in process]
Source: Circulation - Category: Cardiology Authors: Tags: Circulation Source Type: research
Letter by Thomopoulos and Michalopoulou Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". Circulation. 2018 Jun 12;137(24):2656-2657 Authors: Thomopoulos C, Michalopoulou H PMID: 29891622 [PubMed - in process]
Source: Circulation - Category: Cardiology Authors: Tags: Circulation Source Type: research
Letter by Del Pinto et al Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". Circulation. 2018 Jun 12;137(24):2654-2655 Authors: Del Pinto R, Ferri C, Borghi C PMID: 29891621 [PubMed - in process]
Source: Circulation - Category: Cardiology Authors: Tags: Circulation Source Type: research
Date: June 18, 2018 Issue #:  1549Summary:  The FDA has approved the HMG-CoA reductase inhibitor (statin) pitavastatin magnesium (Zypitamag– Zydus) for use in adults with primary hyperlipidemia or mixed dyslipidemia. The FDA considers pitavastatin magnesium bioequivalent to pitavastatin calcium(Livalo), which was approved in 2009.1Statins remain the treatment of choice for most patients who require lipid-lowering therapy. Taken as an adjunct to diet modification, increased exercise, and smoking cessation, statins can reduce the risk of primary and secondary cardiovascular events and death...
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Source Type: research
More News: Cardiology | Cholesterol | Health | Heart | Stroke